Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. News
  7. Summary
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Abivax : releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting

06/07/2021 | 12:01pm EDT

DGAP-News: ABIVAX / Key word(s): AGM/EGM
Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting

07.06.2021 / 18:00
The issuer is solely responsible for the content of this announcement.


Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting

Shareholders approved all proposed resolutions

PARIS, France, June 7, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held its ordinary annual and extraordinary general meeting of shareholders on June 4, 2021, which was chaired by Philippe Pouletty, Chairman of the Board of directors, without the physical presence of the shareholders.

The shareholders have adopted all the resolutions approved by the Board of Directors and, in particular, the financial statements for the 2020 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of Directors related to financial transactions.

Shareholders also approved the reappointments of Philippe Pouletty, Truffle Capital, Santé Holding SRL and Corinna Zur Bonsen-Thomas as Board members.

Details on the vote results will be available on the company's website.

About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63
 
Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254
 
Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22
 
Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24
Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84
Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017


07.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


1205047  07.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1205047&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about ABIVAX
07/23Abivax annonce la mise à disposition d'un prospectus dans le cadre de son aug..
DJ
07/23Abivax publishes a prospectus in the context of its capital increase and bond..
DJ
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
07/23ABIVAX SOCIETE ANONYME : Prices $100 Million Capital Raise to Fund Clinical Prog..
MT
07/23ABIVAX SOCIETE ANONYME : announces the pricing of its oversubscribed capital inc..
PU
07/23PRESS RELEASE : Abivax announces the pricing of -4-
DJ
07/23PRESS RELEASE : Abivax announces the pricing of -3-
DJ
07/23PRESS RELEASE : Abivax announces the pricing of -2-
DJ
07/23PRESS RELEASE : Abivax announces the pricing of its oversubscribed capital incre..
DJ
07/23Abivax annonce le succès de son augmentation de -4-
DJ
More news
Financials
Sales 2021 99,4 M 118 M 118 M
Net income 2021 8,60 M 10,2 M 10,2 M
Net cash 2021 50,3 M 59,6 M 59,6 M
P/E ratio 2021 38,9x
Yield 2021 -
Capitalization 505 M 600 M 599 M
EV / Sales 2021 4,57x
EV / Sales 2022 662x
Nbr of Employees 27
Free-Float 71,6%
Chart ABIVAX
Duration : Period :
ABIVAX Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 30,25 €
Average target price 57,80 €
Spread / Average Target 91,1%
EPS Revisions
Managers and Directors
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ABIVAX-12.06%600
MODERNA, INC.230.85%138 784
LONZA GROUP AG21.77%56 806
IQVIA HOLDINGS INC.38.81%47 656
CELLTRION, INC.-27.16%31 282
SEAGEN INC.-12.38%26 668